Provided by Tiger Fintech (Singapore) Pte. Ltd.

HilleVax, Inc.

1.94
+0.02501.31%
Volume:439.70K
Turnover:843.02K
Market Cap:95.99M
PE:-0.90
High:1.95
Open:1.93
Low:1.88
Close:1.91
Loading ...

Company Profile

Company Name:
HilleVax, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
14
Office Location:
321 Harrison Avenue,5th floor,Boston,Massachusetts,United States
Zip Code:
02118
Fax:
- -
Introduction:
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Rob Hershberg
Chairman, President and Chief Executive Officer
Aditya Kohli
Chief Operating Officer and Director
Gary Dubin
Director
Jaime Sepulveda
Director
Jeri Hilleman
Director
Julie Gerberding
Director
Patrick Heron
Director
Shelley Chu
Director
Susan Silbermann
Director

Shareholders

Name
Position
Rob Hershberg
Chairman, President and Chief Executive Officer
Aditya Kohli
Chief Operating Officer and Director
David Socks
Chief Financial Officer and Chief Business Officer
Astrid Borkowski
Chief Medical Officer